Skip to Content

Sanofi SA SAN

Morningstar Rating
€88.37 +0.20 (0.23%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

SAN is trading at a 22% discount.
Price
€88.17
Fair Value
€511.00
Uncertainty
Medium
1-Star Price
€632.51
5-Star Price
€53.20
Economic Moat
Mzr
Capital Allocation
Djjxjdnsd

Bulls Say, Bears Say

Bulls

Sanofi is launching immunology drug Dupixent in several indications and the drug holds strong pricing power and major blockbuster potential across several indications.

Bears

Sanofi's deep entrenchment in China could come under duress, as Chinese officials are aggressively reviewing drug-marketing and pricing practices.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SAN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
€88.17
Day Range
€88.0389.17
52-Week Range
€80.60105.18
Bid/Ask
€88.37 / €88.39
Market Cap
€110.14 Bil
Volume/Avg
311,772 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
10.04
Price/Sales
2.39
Dividend Yield (Trailing)
4.04%
Dividend Yield (Forward)
4.26%
Total Yield
4.40%

Company Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
87,994

Competitors

Valuation

Metric
SAN
MRK
PFE
Price/Earnings (Normalized)
10.0484.6214.27
Price/Book Value
1.608.551.67
Price/Sales
2.395.382.53
Price/Cash Flow
11.6721.2613.63
Price/Earnings
SAN
MRK
PFE

Financial Strength

Metric
SAN
MRK
PFE
Quick Ratio
0.830.680.58
Current Ratio
1.271.250.91
Interest Coverage
11.032.330.74
Quick Ratio
SAN
MRK
PFE

Profitability

Metric
SAN
MRK
PFE
Return on Assets (Normalized)
8.05%3.59%4.98%
Return on Equity (Normalized)
14.38%9.12%10.90%
Return on Invested Capital (Normalized)
10.85%5.88%7.28%
Return on Assets
SAN
MRK
PFE
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoJkdzlvkzDtpzy$695.3 Bil
JNJ
Johnson & JohnsonQprmzvwvYnyt$359.3 Bil
MRK
Merck & Co IncYpdlzsmnXgtv$321.5 Bil
ABBV
AbbVie IncMpddnpvyXfxrd$297.3 Bil
AZN
AstraZeneca PLC ADRFtpjjkvzVvg$215.8 Bil
RHHBY
Roche Holding AG ADRTgrlxjgtqTlnvm$199.7 Bil
NVS
Novartis AG ADRFmkfclhpSpbt$196.0 Bil
PFE
Pfizer IncJwjvdjmtqXxlb$148.7 Bil
AMGN
Amgen IncDvjjzsqkdyNdbh$145.8 Bil
SNY
Sanofi SA ADRTgybxysHgczc$117.3 Bil

Sponsor Center